loading page

18F-FDG-PET and PET/CT as a diagnostic method for Ewing sarcoma: a systematic review and meta-analysis.
  • +5
  • Ishith Seth,
  • Nimish Seth,
  • Gabriella Bulloch,
  • Adrian Siu,
  • Allen Guo,
  • Rukhmini Chatterjee,
  • Michael MacManus,
  • Leo Donnan
Ishith Seth
Illawarra Shoalhaven Local Health District
Author Profile
Nimish Seth
Alfred Health
Author Profile
Gabriella Bulloch
The University of Melbourne Melbourne Medical School
Author Profile
Adrian Siu
Illawarra Shoalhaven Local Health District
Author Profile
Allen Guo
University of New South Wales Faculty of Medicine
Author Profile
Rukhmini Chatterjee
Illawarra Shoalhaven Local Health District
Author Profile
Michael MacManus
Peter MacCallum Cancer Centre
Author Profile
Leo Donnan
The Royal Children's Hospital Melbourne
Author Profile

Abstract

Purpose: The aim of this study was to evaluate the diagnostic accuracy of 18-fluorodeoxyglucose-positron emission tomography (18F-FDG-PET) and positron emission tomography/computed tomography (PET/CT) in imaging primary and metastatic lesions in Ewing sarcoma (ES). Methods: PubMed, Cochrane, Scopus, and Web of Science were searched for relevant studies. Data concerning 18F-FDG-PET/CT diagnostic accuracy were extracted and then analysed using Open Meta-analyst software. Reported diagnostic accuracy outcomes included sensitivity, specificity, negative likelihood ratio (NLR), positive likelihood ratio (PLR), and diagnostic odds ratio. Results: 31 studies with a total of 735 patients were included in this meta-analysis. The sensitivity and specificity of 18F-FDG PET/CT were: 92.6% and 74.1% for total ES lesions, 96.7% and 68.3% for ES primary lesions, 76.1% and 92.4% for lung metastasis, 83.9% and 93.2% for bone metastasis and 89.9% and 92.6% for ES recurrence respectively. Conclusion: 18F-FDG PET/CT is sensitive and accurate in diagnosing, staging, and detecting the recurrence of ES compared to non-PET imaging. It has high specificity for diagnosing recurrence of ES as well as lung and bone metastases.

Peer review status:UNDER REVIEW

01 Aug 2021Submission Checks Completed
01 Aug 2021Assigned to Editor
01 Aug 2021Submitted to Pediatric Blood & Cancer
07 Aug 2021Reviewer(s) Assigned
08 Sep 2021Review(s) Completed, Editorial Evaluation Pending
14 Sep 2021Editorial Decision: Revise Major
18 Sep 20211st Revision Received
18 Sep 2021Submission Checks Completed
18 Sep 2021Assigned to Editor
21 Sep 2021Reviewer(s) Assigned
21 Sep 2021Review(s) Completed, Editorial Evaluation Pending